文献速递骨软组织肉瘤与黑色素瘤

新辅助达拉非尼联合曲美替尼治疗可切除IIIB-C期BRAFV600突变黑色素瘤的II期试验

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2019-06-03

NeoCombi是一项单臂、开放标签、单中心II期试验,纳入35例可切除临床IIIB-C期BRAFV600突变黑色素瘤患者,接受12周新辅助达拉非尼联合曲美替尼治疗后手术,再辅助治疗40周。

要点

  • 新辅助达拉非尼联合曲美替尼在可切除IIIB-C期BRAFV600突变黑色素瘤中RECIST缓解率达86%。
  • 所有35例患者均达到病理缓解,其中49%为病理完全缓解。
  • 治疗相关严重不良事件发生率17%,3-4级不良事件发生率29%,无治疗相关死亡。

核心结论

  • 新辅助达拉非尼联合曲美替尼治疗可切除IIIB-C期BRAFV600突变黑色素瘤可获得高比例的RECIST缓解和病理缓解,且新辅助期间无进展。

研究设计与样本

  • 单臂、开放标签、单中心II期试验,在澳大利亚黑色素瘤研究所进行,纳入35例可切除临床IIIB-C期BRAFV600突变黑色素瘤患者。
  • 患者接受达拉非尼150 mg口服每日两次联合曲美替尼2 mg口服每日一次,共52周(12周新辅助治疗后完全切除原发瘤床,随后40周辅助治疗)。
  • 主要终点为病理完全缓解率和第12周RECIST缓解率,按方案分析。

主要发现

  • 中位随访27个月(IQR 21-36),切除时30例(86%)达到RECIST缓解,其中16例(46%;95% CI 29-63)完全缓解,14例(40%;24-58)部分缓解。
  • 5例(14%;95% CI 5-30)疾病稳定,无患者进展。
  • 所有35例患者均达到病理缓解,其中17例(49%;95% CI 31-66)病理完全缓解,18例(51%;34-69)非完全病理缓解。

临床怎么用

  • 对于RECIST可测量、可切除的III期BRAFV600突变黑色素瘤,可考虑新辅助达拉非尼联合曲美替尼治疗。

局限性

  • 单臂、开放标签、单中心设计,样本量较小(35例),随访时间有限(中位27个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant dabrafenib plus trametinib therapy improves relapse-free survival in patients with resected stage III melanoma. We aimed to ascertain the proportion of patients who would have a pathological response and a response according to Response Evaluation Criteria in Solid Tumors (RECIST) after neoadjuvant dabrafenib plus trametinib therapy for resectable clinical stage III melanoma. METHODS: NeoCombi was a single-arm, open-label, single-centre, phase 2 study done at Melanoma Institute Australia (Sydney, NSW, Australia). Eligible patients were adults (aged ≥18 years) with histologically confirmed, resectable, RECIST-measurable, clinical stage IIIB-C (American Joint Committee on Cancer [AJCC] 7th edition), BRAFV600-mutant melanoma, and had an Eastern Cooperative Oncology Group performance status of 1 or lower. Patients received 150 mg dabrafenib orally, twice daily, plus 2 mg trametinib orally, once daily, for 52 weeks (12 weeks of neoadjuvant therapy before complete resection of the pre-therapy tumour bed, and 40 weeks of adjuvant therapy thereafter). CT and PET scans were done at baseline and before resection. The primary outcomes were the proportion of patients achieving a complete pathological response and the proportion of patients achieving a response according to RECIST at week 12, analysed as per protocol. This trial is registered with ClinicalTrials.gov, NCT01972347, and follow-up of patients is ongoing. FINDINGS: Between Aug 20, 2014, and April 19, 2017, 40 patients were screened, of whom 35 eligible patients were enrolled, received neoadjuvant dabrafenib plus trametinib, and underwent resection. At the data cutoff (Sept 24, 2018), median follow-up was 27 months (IQR 21-36). At resection, 30 (86%) patients achieved a RECIST response; 16 (46%; 95% CI 29-63) had a complete response and 14 (40%; 24-58) had a partial response. Five patients (14%; 95% CI 5-30) had stable disease, and no patients progressed. After resection and pathological evaluation, all 35 patients achieved a pathological response, of whom 17 (49%; 95% CI 31-66) patients had a complete pathological response and 18 (51%; 95% CI 34-69) had a non-complete pathological response. Treatment-related serious adverse events occurred in six (17%) of 35 patients and grade 3-4 adverse events occurred in ten (29%) patients. No treatment-related deaths were reported. INTERPRETATION: Neoadjuvant dabrafenib plus trametinib therapy could be considered in the management of RECIST-measurable resectable stage III melanoma as it led to a high proportion of patients achieving a complete response according to RECIST and a high proportion of patients achieving a complete pathological response, with no progression during neoadjuvant therapy. FUNDING: GlaxoSmithKline; Novartis; National Health and Medical Research Council, Australia; and Melanoma Institute Australia.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Long GV, Saw RPM, Lo S, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 2019. PMID: 31171444. doi:10.1016/S1470-2045(19)30331-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。